VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:VBIV
- CUSIP: N/A
- Web: www.vbivaccines.com
Capitalization:- Market Cap: $173.46 million
- Outstanding Shares: 40,060,000
Average Prices:- 50 Day Moving Avg: $4.29
- 200 Day Moving Avg: $4.35
- 52 Week Range: $2.75 - $6.60
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: Infinity
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $626,999.00
- Price / Sales: 276.65
- Book Value: $1.89 per share
- Price / Book: 2.29
Profitability:Debt:- Debt-to-Equity Ratio: 0.16%
- Current Ratio: 3.31%
- Quick Ratio: 3.19%
Misc:- Average Volume: 95,433 shs.
- Short Ratio: 3.73
Frequently Asked Questions for VBI Vaccines (NASDAQ:VBIV)
What is VBI Vaccines' stock symbol?
VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV."
Where is VBI Vaccines' stock going? Where will VBI Vaccines' stock price be in 2017?
3 brokers have issued 12 month price targets for VBI Vaccines' stock. Their predictions range from $6.00 to $6.00. On average, they anticipate VBI Vaccines' stock price to reach $6.00 in the next twelve months. View Analyst Ratings for VBI Vaccines.
Who are some of VBI Vaccines' key competitors?
Some companies that are related to VBI Vaccines include Celldex Therapeutics (CLDX), Edge Therapeutics (EDGE), Idera Pharmaceuticals (IDRA), SIGA Technologies (SIGA), Codexis (CDXS), Ardelyx (ARDX), Anavex Life Sciences Corp. (AVXL), Osiris Therapeutics (OSIR), MediWound (MDWD), 22nd Century Group (XXII), Conatus Pharmaceuticals (CNAT), OncoMed Pharmaceuticals (OMED), Pluristem Therapeutics (PSTI), VIVUS (VVUS), CytRx Corporation (CYTR), Ophthotech Corporation (OPHT), Mirati Therapeutics (MRTX) and Nexvet Biopharma PLC (NVET).
Who owns VBI Vaccines stock?
VBI Vaccines' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (16.40%), Clarus Ventures LLC (6.72%), Cambridge Investment Research Advisors Inc. (3.44%), Vanguard Group Inc. (0.45%), KCG Holdings Inc. (0.23%) and EAM Investors LLC (0.19%). View Institutional Ownership Trends for VBI Vaccines.
Who sold VBI Vaccines stock? Who is selling VBI Vaccines stock?
Who bought VBI Vaccines stock? Who is buying VBI Vaccines stock?
VBI Vaccines' stock was purchased by a variety of institutional investors in the last quarter, including KCG Holdings Inc., EAM Investors LLC, Goldman Sachs Group Inc., Morgan Stanley, Bank of Montreal Can and Geode Capital Management LLC. View Insider Buying and Selling for VBI Vaccines.
How do I buy VBI Vaccines stock?
Shares of VBI Vaccines can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is VBI Vaccines' stock price today?
One share of VBI Vaccines stock can currently be purchased for approximately $4.33.
MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for VBI Vaccines (NASDAQ:VBIV) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $6.00 (38.57% upside) |
Analysts' Ratings History for VBI Vaccines (NASDAQ:VBIV)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/15/2017 | Noble Financial | Reiterated Rating | Buy | | Low |  |
| 10/10/2016 | Laidlaw | Initiated Coverage | Buy | $6.00 | N/A | |
| 7/26/2016 | Ladenburg Thalmann Financial Services | Initiated Coverage | Buy | | N/A | |
(Data available from 6/24/2015 forward)
Earnings History for VBI Vaccines (NASDAQ:VBIV)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for VBI Vaccines (NASDAQ:VBIV)Current Year EPS Consensus Estimate: $-0.69 EPS
Dividend History for VBI Vaccines (NASDAQ:VBIV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for VBI Vaccines (NASDAQ:VBIV)Insider Ownership Percentage: 54.50%
Institutional Ownership Percentage: 29.18%
Insider Trades by Quarter for VBI Vaccines (NASDAQ:VBIV)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/6/2016 | Perceptive Advisors Llc | Major Shareholder | Buy | 3,383,955 | $3.05 | $10,321,062.75 | |
| 8/14/2015 | Perceptive Advisors Llc | Major Shareholder | Buy | 650,000 | $2.08 | $1,352,000.00 | |
| 9/30/2013 | Murray George Smith | CFO | Buy | 3,027 | $1.13 | $3,420.51 | |
| 8/21/2013 | Murray George Smith | CFO | Buy | 8,973 | $1.17 | $10,498.41 | |
(Data available from 1/1/2013 forward)
Headline Trends for VBI Vaccines (NASDAQ:VBIV)
Latest Headlines for VBI Vaccines (NASDAQ:VBIV)
| Source: |
|
| Date | Headline |
|---|
 | VBI Vaccines (VBIV) Announces Positive Outcome from Phase III Pre-IND Discussions with FDA for Hepatitis B Vaccine, Sci-B-Vac
www.streetinsider.com - June 21 at 6:25 AM |
 | VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM)
finance.yahoo.com - June 19 at 8:35 AM |
 | VBI Vaccines, Inc. (VBIV) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - June 16 at 10:06 AM |
| VBI Vaccines, Inc. (VBIV) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - June 14 at 2:20 PM |
| VBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 5 at 11:22 AM |
| VBI Vaccines, Inc. - (VBIV) Downgraded by TheStreet to "D+"
www.americanbankingnews.com - June 5 at 12:28 AM |
| VBI Vaccines, Inc. - (VBIV) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - June 3 at 12:12 PM |
| VBI Vaccines, Inc. - (VBIV) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - June 2 at 11:58 AM |
| VBI Vaccines, Inc. - (VBIV) Receives Buy Rating from Noble Financial
www.americanbankingnews.com - May 28 at 8:56 PM |
| VBI Vaccines, Inc. - (VBIV) Given Buy Rating at Noble Financial
www.americanbankingnews.com - May 6 at 5:44 PM |
| VBI Vaccines, Inc. - (VBIV) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 6 at 9:08 AM |
| VBI Vaccines, Inc. - (VBIV) Getting Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - May 3 at 3:52 PM |
| VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study
finance.yahoo.com - May 2 at 6:34 PM |
| VBI Vaccines, Inc. - (VBIV) Earning Somewhat Positive Media Coverage, Study Finds
www.americanbankingnews.com - April 29 at 11:35 AM |
| VBI Vaccines, Inc. - (VBIV) Earns Daily News Sentiment Rating of 0.04
www.americanbankingnews.com - April 26 at 10:20 AM |
| 3 Different Companies, 3 Different Approaches to Tumors
finance.yahoo.com - April 24 at 6:51 PM |
| VBI Vaccines, Inc. - (VBIV) Earning Somewhat Positive News Coverage, Report Shows
www.americanbankingnews.com - April 19 at 9:39 AM |
| VBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress
finance.yahoo.com - April 7 at 1:18 PM |
| VBI Vaccines Appoints Avi Mazaltov as Global Head of Manufacturing and SciVac General Manager; Rehovot, Israel Site
finance.yahoo.com - March 31 at 6:26 AM |
| Zacks: Brokerages Set $8.50 Price Target for VBI Vaccines, Inc. - (VBIV)
www.americanbankingnews.com - March 29 at 11:44 AM |
 | Meet VBI Vaccines, The Biotech Up 100% In 2017
feeds.benzinga.com - March 7 at 1:36 PM |
| VBI Vaccines (VBIV) Announces Positive Response from Health Canada's Initial Evaluation of Sci-B-Vac Phase III Clinical Program
www.streetinsider.com - February 23 at 3:06 AM |
 | VBI VACCINES INC
www.finanznachrichten.de - February 23 at 3:06 AM |
 | VBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program
us.rd.yahoo.com - February 22 at 10:46 AM |
| VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical Study
us.rd.yahoo.com - February 7 at 3:49 PM |
| VBIV: Notable Investors and Multiple Upcoming Catalysts Make VBIV a Stock to Watch in 2017
finance.yahoo.com - February 3 at 6:35 AM |
| VBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors
us.rd.yahoo.com - December 6 at 11:45 AM |
| 8:42 am VBI Vaccines completes sale of 3.475 mln common shares at $3.05/share in a private placement to Perceptive Advisors, for total gross proceeds of approx. $10.6 mln; co also announced $13 mln in secured debt
us.rd.yahoo.com - December 6 at 11:45 AM |
| Trump Victory Gives Life to Pharma,Biotech - Take a Look at VBI Vaccines
finance.yahoo.com - November 11 at 7:57 PM |
| VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
finance.yahoo.com - November 10 at 11:49 AM |
 | Likely Clinton Victory Has Created an Opportunity for This Stock
www.thestreet.com - November 7 at 9:12 PM |
| VBI Vaccines to Present Zika Vaccine Program Poster at the Keystone Symposia on Translational Vaccinology for Global Health
finance.yahoo.com - October 27 at 10:33 AM |
| VBI Vaccines (VBIV) Says Pre-IND Meeting with FDA Over VBI-1901 Complete; Fast-Track Designation Under Consideration
www.streetinsider.com - October 13 at 11:56 AM |
 | Some of the Biotech Industry's Most Recognized Investors Are Focusing on the Zika Vaccine
www.huffingtonpost.com - October 13 at 11:56 AM |
| VBI Vaccines Completes Pre-IND Meeting for its Glioblastoma Immunotherapy Candidate
finance.yahoo.com - October 11 at 7:42 PM |
| VBI Vaccines to Present at the World Vaccine Congress Europe
finance.yahoo.com - October 5 at 7:46 PM |
| VBI Vaccines Announces Results of Annual General and Special Meeting
finance.yahoo.com - September 26 at 7:57 PM |
| VBI's Sci-B-Vac Should Take Market Share In The Hepatitis B Vaccine Market
finance.yahoo.com - September 21 at 7:28 PM |
 | MSTX Crashes On EPIC Data, MIRN Ditches MRX34, More Good News From SRPT
www.rttnews.com - September 21 at 11:47 AM |
| VBI Vaccines Completes Enrollment of Participants in the Phase I Clinical Trial of Its Preventative Cytomegalovirus Vaccine Candidate
finance.yahoo.com - September 21 at 11:47 AM |
| VBI Vaccines: The Safer Alternative to the Struggling Dynavax Technologies
finance.yahoo.com - September 6 at 7:37 AM |
| An In-Depth Look at the VBI Vaccines CMV Study
finance.yahoo.com - August 25 at 8:21 PM |
| VBI Vaccines to Continue Enrolling Participants in the Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate Following Successful Data Safety Monitoring Board Review
finance.yahoo.com - August 25 at 7:41 AM |
| Does This Under-the-Radar Company Hold the Key to a Zika Vaccine?
www.thestreet.com - August 9 at 8:27 PM |
 | Understanding The Zika Virus And Which Companies Are Working To Eliminate The Problem
seekingalpha.com - July 31 at 7:23 PM |
| Coverage initiated on VBI Vaccines by Ladenburg Thalmann
finance.yahoo.com - July 26 at 7:41 AM |
| Getting to Know VBI Vaccines
finance.yahoo.com - July 13 at 1:04 PM |
| VBI Vaccines Begins Enrolling Patients in a Phase I Trial of its Preventative Cytomegalovirus Vaccine Candidate
finance.yahoo.com - June 23 at 10:39 AM |
| 8:38 am VBI Vaccines closes private placement of ~3.27 mln shares of common stock at ~$4.16/share for total gross proceeds of ~$13.6 mln
finance.yahoo.com - June 21 at 8:38 AM |
| VBI Vaccines Announces Closing of $13.6 Million Private Placement
finance.yahoo.com - June 21 at 8:30 AM |
VBI Vaccines (VBIV) Chart for Saturday, June, 24, 2017
